文献速递心境障碍

氯胺酮抗抑郁作用机制综述

Mechanisms of ketamine action as an antidepressant.
PubMed 文献 · Mol Psychiatry · 2018-03-13

本综述系统梳理了氯胺酮作为抗抑郁药的分子机制假说,包括突触或GluN2B选择性突触外NMDAR抑制、抑制GABA能中间神经元上的NMDAR、抑制外侧缰核神经元NMDAR依赖的爆发性放电以及AMPA受体激活的作用。同时讨论了氯胺酮抗抑郁作用与调节突触可塑性的下游机制(BDNF、eEF2、mTOR和GSK-3)的联系,以及不直接涉及NMDAR抑制的机制(包括(R)-氯胺酮对映体和HNK代谢物,特别是(2R,6R)-HNK)。提出的机制可能互补地发挥急性突触可塑性变化,导致兴奋性突触持续增强,这是抗抑郁行为所必需的。

要点

  • 氯胺酮单次亚麻醉剂量可诱导快速持久的抗抑郁作用
  • 多种NMDAR抑制假说及AMPA受体激活参与其抗抑郁机制
  • 下游BDNF、eEF2、mTOR和GSK-3通路调节突触可塑性

核心结论

  • 氯胺酮的抗抑郁作用由多种互补机制介导,急性改变突触可塑性导致兴奋性突触持续增强。
  • 理解其分子机制有助于开发模拟抗抑郁作用但缺乏不良反应的新一代药物。

研究设计与样本

  • 综述文章,总结临床前研究证据,未报告系统检索范围。

主要发现

  • 临床研究表明单次亚麻醉剂量氯胺酮诱导快速持久抗抑郁作用。
  • 临床前研究聚焦于阐明氯胺酮抗抑郁作用的分子机制。
  • 假说包括突触或GluN2B选择性突触外NMDAR抑制、抑制GABA能中间神经元NMDAR、抑制外侧缰核NMDAR依赖爆发性放电及AMPA受体激活。
  • 下游机制涉及BDNF、eEF2、mTOR和GSK-3调节突触可塑性。
  • 不直接抑制NMDAR的机制包括(R)-氯胺酮对映体和HNK代谢物(特别是(2R,6R)-HNK)的作用。

临床怎么用

  • 氯胺酮的广泛使用受其滥用潜力和分离特性限制。
  • 机制认识为开发模拟抗抑郁作用但缺乏不良反应的新型药物提供靶点。

局限性

  • 综述未报告系统检索策略或纳入排除标准。
  • 所讨论机制多基于临床前研究,尚未在临床中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions. Although this finding has been met with enthusiasm, ketamine's widespread use is limited by its abuse potential and dissociative properties. Recent preclinical research has focused on unraveling the molecular mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine's antidepressant actions but lack its undesirable effects. Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation. We also discuss links between ketamine's antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3). Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine's (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed. Proposed mechanisms of ketamine's action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions. Understanding the molecular mechanisms underpinning ketamine's antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018. PMID: 29532791. doi:10.1038/mp.2017.255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。